ArticleJournal of virology2025
The producer cell type of HSV-1 alters the proteomic contents and infectious capacity of virions.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell type-specific differences in herpes simplex virus type 1 infection and dependency on ICP27.Journal of virology · 2026Article
- Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.The Journal of general virology · 2026Article
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
The cell that a virus replicates in, that is, the producer cell, can alter the macromolecular composition and infectious capacity of the virions that are produced. Herpes simplex virus type 1 (HSV-1) primarily infects keratinocytes of the epidermis or oral mucosa prior to establishing latency in neurons of the peripheral nervous system, where the virus can persist for the lifetime of the host. Many cell lines that are used to amplify HSV-1 are derived from species and tissue types that are less physiologically relevant to HSV-1 disease. To understand whether the producer cell type influences HSV-1 infection, we tested the infectivity of HSV-1 derived from immortalized African green monkey kidney cells (Vero), immortalized human keratinocytes (HaCaT), and primary human foreskin fibroblasts (HFF-1). We observed that the producer cell type alters the capacity of HSV-1 to produce viral transcripts, proteins, and infectious virions from infected cells and susceptibility to inhibition of replication by interferon treatment. HaCaT-derived HSV-1 consistently exhibited enhanced replication over HFF-1 or Vero-derived virus. To determine whether the producer cell type changes the protein composition of virions, we performed an untargeted LC/MS-MS analysis of virions purified from each cell line. Comparison of virion-associated proteins revealed quantitative differences in composition of both cellular and viral proteins, including ICP0, pUL24, and pUL42. These results highlight the influence that the producer cell type has on HSV-1 infection outcomes and suggest that cell-type-specific factors can alter HSV-1 and impact viral replication. IMPORTANCE: Approximately 67% of the human population harbors herpes simplex virus type 1 (HSV-1) infection. To study HSV-1, laboratories utilize several different cell lines to propagate HSV-1 for downstream experiments. The type of cell used to produce a virus, that is, the producer cell type, can alter the macromolecular composition, immunogenicity, and infectivity of the virions that are produced across several virus families. We found that the producer cell type of HSV-1 alters virion infectivity and virion protein composition. Therefore, the producer cell type may have implications in the spread of HSV-1 and subsequent disease outcomes in humans. Our results also raise concerns about how the use of different cell types to propagate HSV-1 may alter the outcome, interpretation, and reproducibility of experimental results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.